印度新增37.9万宗确诊续创新高 连续七日单日逾30万宗
印度疫情续恶化,过去24小时新增37.93万宗新冠肺炎确诊病例,连续七日单日录逾30万宗确诊,新增3,645宗新冠肺炎死亡病例,均创历史新高。印度累计确诊病例达1,838万宗,死亡病例累计达20.48万宗。
美国白宫昨(28日)公布,正向印度提供价值逾1亿美元的物资,协助对抗疫情,周四(29日)开始抵达,并持续至下周,包括1,000个氧气瓶、1,500万个N95口罩及100万套快速测试套装。美国亦指示阿斯利康(AZN.US)将其疫苗订单转至印度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.